Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma.

NCT00066092 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00066092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00066092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma.
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
October 31, 2004
Enrollment
41 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hematology, hodgkin's lymphoma, lymphoma, non-hodgkin's lymphoma, oncology